Fidelity Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $446M | Buy |
6,971,361
+147,661
| +2% | +$7.66M | 0.02% | 598 |
|
|
2026
Q1 | $329M | Buy |
6,823,700
+5,180,837
| +315% | +$230M | 0.02% | 658 |
|
|
2025
Q4 | $67.8M | Buy |
1,642,863
+843,108
| +105% | +$33.8M | ﹤0.01% | 1321 |
|
|
2025
Q3 | $31.1M | Sell |
799,755
-7,143
| -0.9% | -$232K | ﹤0.01% | 1616 |
|
|
2025
Q2 | $22.3M | Buy |
806,898
+2,755
| +0.3% | +$70.1K | ﹤0.01% | 1660 |
|
|
2025
Q1 | $17.9M | Buy |
804,143
+98,802
| +14% | +$2.03M | ﹤0.01% | 1718 |
|
|
2024
Q4 | $14M | Buy |
705,341
+8,531
| +1% | +$195K | ﹤0.01% | 1846 |
|
|
2024
Q3 | $17.4M | Buy |
696,810
+694,928
| +36,925% | +$16.9M | ﹤0.01% | 1758 |
|
|
2024
Q2 | $35.1K | Sell |
1,882
-449
| -19% | -$8.41K | ﹤0.01% | 3803 |
|
|
2024
Q1 | $46K | Buy |
2,331
+46
| +2% | +$898 | ﹤0.01% | 3628 |
|
|
2023
Q4 | $40.1K | Buy |
2,285
+89
| +4% | +$1.46K | ﹤0.01% | 3616 |
|
|
2023
Q3 | $38.1K | Buy |
2,196
+112
| +5% | +$1.89K | ﹤0.01% | 3480 |
|
|
2023
Q2 | $29.3K | Buy |
2,084
+83
| +4% | +$1.11K | ﹤0.01% | 3683 |
|
|
2023
Q1 | $21.5K | Sell |
2,001
-228,992
| -99% | -$3.02M | ﹤0.01% | 3813 |
|
|
2022
Q4 | $3.46M | Sell |
230,993
-15,371
| -6% | -$224K | ﹤0.01% | 2222 |
|
|
2022
Q3 | $3.16M | Buy |
246,364
+118
| +0% | +$1.34K | ﹤0.01% | 2300 |
|
|
2022
Q2 | $2.39M | Buy |
246,246
+36
| +0% | +$336 | ﹤0.01% | 2452 |
|
|
2022
Q1 | $2.45M | Buy |
246,210
+64,070
| +35% | +$679K | ﹤0.01% | 2550 |
|
|
2021
Q4 | $2.14M | Sell |
182,140
-123,400
| -40% | -$1.52M | ﹤0.01% | 2548 |
|
|
2021
Q3 | $3.48M | Hold |
305,540
| – | – | ﹤0.01% | 2447 |
|
|
2021
Q2 | $4.26M | Sell |
305,540
-153,700
| -33% | -$2.33M | ﹤0.01% | 2377 |
|
|
2021
Q1 | $8.5M | Sell |
459,240
-47,900
| -9% | -$980K | ﹤0.01% | 2088 |
|
|
2020
Q4 | $8.96M | Hold |
507,140
| – | – | ﹤0.01% | 2006 |
|
|
2020
Q3 | $7.77M | Buy |
507,140
+244,334
| +93% | +$4.59M | ﹤0.01% | 1914 |
|
|
2020
Q2 | $6.7M | Buy |
262,806
+140,906
| +116% | +$2.94M | ﹤0.01% | 1953 |
|
|
2020
Q1 | $1.89M | Buy |
+121,900
| New | +$1.91M | ﹤0.01% | 2201 |
|
|
2019
Q3 | – | Sell |
-634,539
| Closed | -$8.59M | – | 4033 |
|
|
2019
Q2 | $8.59M | Sell |
634,539
-4,691
| -0.7% | -$72.8K | ﹤0.01% | 1939 |
|
|
2019
Q1 | $11.5M | Hold |
639,230
| – | – | ﹤0.01% | 1810 |
|
|
2018
Q4 | $18M | Sell |
639,230
-138,855
| -18% | -$2.9M | ﹤0.01% | 1600 |
|
|
2018
Q3 | $19M | Sell |
778,085
-125,307
| -14% | -$2.44M | ﹤0.01% | 1697 |
|
|
2018
Q2 | $14.6M | Buy |
+903,392
| New | +$16.3M | ﹤0.01% | 1827 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Fidelity Investments's KNSA Position: Q2 2026 in Review
Fidelity Investments increased its Kiniksa Pharmaceuticals (KNSA) stake by 2.2% in Q2 2026, buying an estimated $7.66M and bringing the position to 6,971,361 shares worth $446M. The position accounts for 0.02% of the portfolio, ranked #598.
Fidelity Investments first reported a position in KNSA in Q2 2018 and has held it in 31 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Fidelity Investments held 6,971,361 shares of Kiniksa Pharmaceuticals worth $446M as of Q2 2026.
- Fidelity Investments bought 147,661 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $7.66M.
- Kiniksa Pharmaceuticals made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #598 holding.
- Fidelity Investments first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.